Key result
Despite consensus that ICD deactivation should be routinely discussed in end-stage heart failure, this rarely occurs in clinical practice due to uncertainty and reluctance to confront death.
Population
Patients with end-stage heart failure and implantable cardioverter defibrillators (ICDs)
Design
Review
Authors
Loading...
Gap persists between consensus and ICD deactivation discussions in end-stage HF; leaves open effective strategies to address clinician barriers.
Despite consensus on the need for routine discussion of ICD deactivation in end-stage heart failure, it rarely occurs in clinical practice due to uncertainty and reluctance to confront death.
Pettit et al. (2012) conducted a review in End-stage heart failure. Implantable cardioverter defibrillators (ICDs) was evaluated. Despite consensus that ICD deactivation should be routinely discussed in end-stage heart failure, this rarely occurs in clinical practice due to uncertainty and reluctance to confront death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: